Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orlance biodefense nucleic acid vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Epidermal
01
Overview
Orlance is developing a biodefense-focused nucleic acid vaccine program targeting a range of high-priority viral threats, including Ebola virus, Dengue virus, Encephalitis viruses, Hantavirus, and xPox (Orthopoxviruses). The vaccines utilize the proprietary **MACH-1** (Micro-particle Associated Nucleic Acid) platform, which is an epidermal powdered gene gun delivery technology. This needle-free system delivers DNA-coated gold microparticles directly into the epidermis, targeting the dense network of antigen-presenting cells to elicit potent and broad immune responses. The platform is designed for rapid deployment and stability, potentially eliminating the need for cold-chain logistics. The program is currently in preclinical development and focuses on both emerging infectious diseases and biothreat agents.
- Other names
- Orlance-Ebola virus-Dengue virus-Encephalitis virus-Hantavirus-xPox virus-nucleic acid vaccine-epidermal-Ebola-Dengue fever-Encephalitis-Hantavirus infection-xPox
Beyond the preview
Go deeper on Orlance biodefense nucleic acid vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orlance biodefense nucleic acid vaccine.